Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
278 hedge funds and large institutions have $6.46B invested in Blueprint Medicines in 2020 Q4 according to their latest regulatory filings, with 70 funds opening new positions, 74 increasing their positions, 104 reducing their positions, and 28 closing their positions.
150% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 28
22% more capital invested
Capital invested by funds: $5.28B → $6.46B (+$1.18B)
18% more funds holding
Funds holding: 236 → 278 (+42)
0.93% less ownership
Funds ownership: 103.62% → 102.68% (-0.93%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
29% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 104
57% less call options, than puts
Call options by funds: $24.7M | Put options by funds: $57.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$285M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$104M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.1M |
| 5 |
BlackRock
New York
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$172M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$122M |
| 3 |
PA
Perceptive Advisors
New York
|
-$61.6M |
| 4 |
DM
Deerfield Management
New York
|
-$42.7M |
| 5 |
Holocene Advisors
New York
|
-$32.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FHA
301
Flagship Harbor Advisors
Boston,
Massachusetts
| – | -$5K | -61 | Closed |
|
|
MIM
302
Macroview Investment Management
Bethesda,
Maryland
| – | -$3K | -30 | Closed |
|
|
CWC
303
Carolinas Wealth Consulting
Charlotte,
North Carolina
| – | -$2K | -20 | Closed |
|
304
Simplex Trading
Chicago,
Illinois
| – | +$53.5K | +508 | New |
|
BPMC Hedge Fund Activity: Q4 2020 in Review
278 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2020, worth a combined $6.46B — up 22% from $5.28B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new BPMC positions and 28 closed out — a net gain of 42 holders — while 74 added to existing stakes and 104 trimmed.
The largest buyer was Lone Pine Capital, opening a new position worth an estimated $285M. The largest seller was Cadian Capital Management, cutting an estimated $172M.
- 278 institutional investors held Blueprint Medicines (BPMC) as of Q4 2020, up from 236 in Q3 2020.
- Funds reported $6.46B of Blueprint Medicines stock for Q4 2020, up 22% quarter-over-quarter.
- 70 funds opened new Blueprint Medicines positions in Q4 2020 and 28 closed out, a net change of +42 holders.
- The largest Blueprint Medicines buyer in Q4 2020 was Lone Pine Capital, an estimated $285M added.
- The largest Blueprint Medicines seller in Q4 2020 was Cadian Capital Management, an estimated $172M sold.
Based on aggregated 13F filings for Q4 2020.